CHARLES E, GRASSLEY, IOWA, CHAIRMAN
DIANNE FEINSTEIN, CALIFORNIA, CO-CHAIRMAN
JOHN CORNYN, TEXAS CHARLES SCHUMER, NEW YORK
JAMES E. RISCH, IDAHO SHELDON WHITEHOUSE, RHODE ISLAND
JEFF SESSIONS, ALABAMA

United States Senate

SENATE CAUCUS ON INTERNATIONAL NARCOTICS CONTROL HART SENATE OFFICE BUILDING, ROOM 818–C WASHINGTON, DC 20510

May 16, 2016

The Honorable Loretta Lynch Attorney General U.S. Department of Justice 950 Pennsylvania Avenue, NW Washington, DC 20530

Dear Attorney General Lynch:

We are writing to follow up on a letter we sent May 13, 2015 requesting that to the Departments of Justice and Health and Human Services conduct a scientific and medical evaluation of cannabidiol. We are grateful that the Departments agreed to conduct this evaluation, and are now requesting an update on its status and the expected date of completion.

Given that many individuals suffer from serious medical conditions that may be alleviated by cannabidiol, it is critical that this evaluation be completed expeditiously.

Thank you for your prompt attention to this important request. We appreciate the steps your Department has already taken to reduce barriers to researching cannabidiol. We look forward to your response, which we respectfully request by June 17, 2016.

Sincerely,

Charles Grassley

Chairman

Dianne Feinstein

Co-Chairman

cc: Sylvia Matthews Burwell, Secretary, Department of Health and Human Services

Chuck Rosenberg, Acting Administrator, Drug Enforcement Administration Robert Califf, M.D., Commissioner, Food and Drug Administration